Company: RCUS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001724521-25-000101
Chunk: 215

Company: Arcus Biosciences, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 215
---
15 $20 $31 $40 

Note 9. Cash, cash equivalents and marketable securities 

The following table summarizes the amortized cost, gross unrealized gains and losses and the fair value of our cash, cash equivalents and marketable securities, all of which are considered available for sale, by type of securities (in millions): Types of securities as of June 30, 2025AmortizedCostUnrealizedGainUnrealizedLoss FairValueMoney market funds$187 $— $— $187 U.S. treasury securities229 — — 229 Corporate securities and commercial paper485 — — 485 U.S. government agency securities2 — — 2 Certificate of deposit24 — — 24 Total cash, cash equivalents and marketable securities$927 $— $— $927 Types of securities as of December 31, 2024AmortizedCostUnrealizedGainUnrealizedLoss FairValueMoney market funds$120 $— $— $120 U.S. treasury securities251 — — 251 Corporate securities and commercial paper592 — — 592 U.S. government agency securities5 — — 5 Certificate of deposit24 — — 24 Total cash, cash equivalents and marketable securities$992 $— $— $992 

15

The following table summarizes the fair values of our cash, cash equivalents and marketable securities by location in the Condensed Consolidated Balance Sheets and contractual maturity (in millions):Location in Condensed Consolidated Balance SheetsContractual MaturityJune 30, 2025December 31, 2024Cash and cash equivalents—$248 $150 Marketable securitiesWithin one year663 828 Long-term marketable securitiesBetween one and three years16 14 Total cash, cash equivalents and marketable securities $927 $992 Realized gains or losses recognized on the sale of available-for-sale marketable securities were not material for the three and six months ended June 30, 2025 and 2024 and are included in Interest and other income, net, in the Condensed Consolidated Statements of Operations. The cost of a security sold is determined using the specific-identification method.We limit the credit risk associated with our investments by placing them with banks and institutions we believe are highly credit worthy and investing in highly rated investments